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a  b  s  t  r  a  c  t
A  toxicological  evaluation  of  4-amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-2-
methylquinoline-3-carboxylic  acid(S9632;  CAS 1359963-68-0),  a ﬂavour  with  modifying  properties,was
completed  for  the  purpose  of  assessing  its  safety  for  use  in food  and  beverage  applications.  No  Phase  I
biotransformations  of S9632  were  observed  in  rat or  human  microsomes  in vitro,  and  in rat  pharma-
cokinetic  studies,  the  compound  was poorly  orally  bioavailable  and  rapidly  eliminated.  S9632 was  not
found  to be mutagenic  or clastogenic  in  vitro,  and  did  not  induce  micronuclei  or indicate  interactions
with  the  mitotic  spindle  in an  in  vivo mouse  micronucleus  assay  at oral  doses  up  to 2000  mg/kg.  In9632
EMA GRAS
ubchronic toxicological evaluation
enetic toxicological evaluation
subchronic  oral  toxicity  studies  in  rats, the  NOEL  was  100  mg/kg/day  (highest  dose  tested)  for  S9632
when  administered  as  a food  ad-mix  for  90 consecutive  days.  Furthermore,  S9632 demonstrated  a lack
of  maternal  toxicity,  as  well  as adverse  effects  on  fetal  morphology  at the  highest  dose  tested,  providing
a  NOEL  of 1000  mg/kg/day  for both  maternal  toxicity  and  embryo/fetal  development  when  administered
orally  during  gestation  to pregnant  rats.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
4-Amino-5-(3-(isopropylamino)-2,2-dimethyl-3-oxopropoxy)-
-methylquinoline-3-carboxylic acid (S9632; CAS 1359963-68-0)
s a ﬂavour with modifying properties (FMP). FMP  is a term used
y the ﬂavour industry to describe ingredients that function as
art of a ﬂavour system, also known as compounded ﬂavours [7],
o modify or enhance the ﬂavour proﬁle of a variety of food and
everages. Similar to the FMPs S6973 and S617 previously reported
1], S9632 is a positive allosteric modulator of the human sweet
eceptor which, in addition to modifying certain aspects of the
Abbreviations: AUC, area under the curve; Cmax, peak plasma concentration;
DA, Food and Drug Administration; FEMA, Flavour and Extract Manufacturers
ssociation of the United States; FMP, ﬂavour with modifying properties; GLP,
ood Laboratory Practices; GMP, Good Manufacturing Practices; HPBL, human
eripheral blood lymphocytes; LC/MS, liquid chromatography with mass spec-
rometry; MC,  methylcellulose; NOAEL, no-observed-adverse-effect-level; NOEL,
o-observed-effect-level; OECD, Organization for Economic Cooperation and Devel-
pment; PCE, polychromatic erythrocytes; PK, pharmacokinetics; RCG, Relative Cell
rowth; RMI, Relative Mitotic Index; Tmax, time to reach Cmax; TK, toxicokinetics.
∗ Corresponding author. Fax: +1 858 404 0750.
E-mail address: amy.arthur@senomyx.com (A.J. Arthur).
ttp://dx.doi.org/10.1016/j.toxrep.2015.08.012
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).ﬂavour proﬁle, allow for a reduction of carbohydrate sweeteners
in food and beverage products while maintaining the desired
sweet taste of natural sugars [19,20,22]. FMPs may not necessarily
have a taste on their own, but work in concert with other ﬂavour
ingredients in a ﬂavour system to change the ﬂavour proﬁle of a
food product, such as by decreasing or increasing the intensity of
speciﬁc ﬂavour characteristics [8]. For example, S9632 has been
shown to function in food and beverage products with reduced
sweetener to restore sweetness, as well as modify other aspects
of the ﬂavour proﬁle, such as caramel, butterscotch and molasses
attributes when present in a butterscotch pudding, or citrus
and cherry attributes when used in a tropical punch beverage
(Senomyx, unpublished data). The structure of S9632 is shown in
Fig. 1.
This substance was reviewed by the Expert Panel of the Flavour
and Extract Manufacturers Association of the United States (FEMA)
and determined to be generally recognized as safe (GRAS) under
the conditions of intended use as a ﬂavour ingredient [7,13] and
therefore is available for use in human food in the United States as
a “FEMA GRAS” ﬂavour ingredient. S9632 was  assigned the FEMA
GRAS Number 4774 in 2012 [13]. S9632 was  also determined to be
safe at the current levels of intake by the Joint FAO/WHO Expert
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
1256 A.J. Arthur et al. / Toxicology Rep
C
2
t
u
o
s
a
t
S
2
P
I
s
i
t
I
M
m
i
A
f
f
A
d
h
G
i
c
r
a
f
m
a
[
t
G
O
l
a
t
U
T
d
w
P
s
T
i
dose (1 mg/kg in a 1% ethanol solution) of S9632 and blood samplesFig. 1. Structures of S9632 and Impurity S9379.
ommittee on Food Additives [11] (assigned JECFA No. 2204 and
204.1 for the S9632-sulfate salt) and has recently been submitted
o the European Union for review. Other jurisdictions permit the
se of S9632 including Japan, Korea, and Mexico (CO-6.12.2013).
The purpose of this publication is to summarize the results
btained from in vitro metabolism and in vivo pharmacokinetic (PK)
tudies, general toxicology studies in rodents, genotoxicity studies,
nd developmental toxicity studies conducted with S9632. Addi-
ional supporting data obtained in these studies is included in a
upplementary Data section in the online publication.
. Materials and methods
The batches of S9632 used for the in vitro metabolism, in vivo
K, genotoxicity, and 28-day range-ﬁnding toxicity studies (Batch
D no. 51837,343 and 52185,558, purity >98.5%), were synthe-
ized at Senomyx (San Diego, CA) using the procedure described
n US Patent No. 8815956 [21]. The batch of S9632 used for
he 90-day subchronic and developmental toxicity studies (Batch
D no. 57341902, purity 98.8%), was synthesized at Cambridge
ajor Laboratories (Germantown, WI)  using the same synthetic
ethod but prepared in conformance with Good Manufactur-
ng Practices (GMPs) as described in the ICH GMP  Guidelines for
PIs [9]. The sodium (S3333), phosphate (S3337) and hemisul-
ate (S1638) salts of S9632 were also prepared at Senomyx
or solubility and bioequivalence studies (purity of each >98%).
 minor impurity (>0.1%), 4-amino-5-(3-(isopropylamino)-2,2-
imethyl-3-oxopropoxy)-2-methylquinoline (S9379, see Fig. 1)
as been observed in various batches of S9632, including the
MP  batch used for the 90-day and developmental toxic-
ty studies; an authentic standard (synthesized at Senomyx)
onﬁrmed the structure of the impurity by liquid chromatog-
aphy with mass spectrometry (LC/MS) and was  used for the
bbreviated Ames (2-strains) assay. The internal standard used
or the pharmacokinetic studies, 4-amino-5-cyclopentyloxy-2-
ethylquinoline-3-carboxylic acid (S0176), was also synthesized
t Senomyx by the procedure described in US Patent No. 8815,956
21].
With the exception of the abbreviated Ames assays, all genetic
oxicology studies were conducted in compliance with the FDA
ood Laboratory Practices (GLP) regulations 21CFR Part 58 [5] and
ECD guidelines [17]. The experimental design for these studies fol-
owed the OECD Guidelines for the Testing of Chemicals - 471, 473,
nd 474 [14–16]. The 28-day dose-range ﬁnding studies and 90-day
oxicology studies in rats were conducted in compliance with the
nited States Food and Drug Administration (FDA) Guidelines [6]
oxicological Principles for the Safety of Food Ingredients; the 90-
ay subchronic toxicology study was also conducted in compliance
ith the FDA Good Laboratory Practice (GLP) Regulations, 21CFR
art 58. The developmental toxicity range-ﬁnder and deﬁnitive
tudies were conducted in accordance with the OECD Guidelines for
esting of Chemicals Guideline 414, Prenatal Developmental Tox-
city Study [18] and the United States FDA Redbook 2000: IV.C.9.borts 2 (2015) 1255–1264
Guidelines for Developmental Toxicity Studies [4] and the FDA GLP
regulations 21CFR Part 58 and OECD guidelines OECD, 1998.
The microsomal metabolism studies on S9632 were conducted
at PharmOptima (Portage, MI). Pharmacokinetic studies and excre-
tion studies on S9632 in rats were conducted at Senomyx (San
Diego, CA). The abbreviated Ames (2-strains) tests on S9632 and
the decarboxylated impurity S9379 were conducted at BioReliance
(Rockville, MD). The other genotoxicity studies, i.e.  bacterial reverse
mutation (5-strain Ames), in vitro chromosome aberration, and
in vivo mouse micronucleus assays, were conducted at Nucro-
Technics (Scarborough, Ontario, Canada). The 28-day and 90-day
subchronic toxicity studies were conducted at MPI  Research (Mat-
tawan, WI). The developmental toxicity study was conducted at
WIL  Research (Ashland, OH). A description of the study designs is
included in the individual study sections below. Detailed data tables
for the genotoxicity, subchronic and developmental toxicity studies
can be found in the Supplementary Data ﬁles published online.
3. Absorption, distribution, metabolism, excretion
The in vitro metabolism of S9632 was studied using both rat and
human liver microsomes. The in vivo metabolism and PK of S9632
was studied in rats, including bioequivalence studies of the S9632
sodium, phosphate, and hemisulfate salts.
3.1. In Vitro metabolism
The potential of S9632 to undergo oxidative metabolism was
investigated using Sprague-Dawley rat and human liver micro-
somes (XenoTech, Lenexa, KS). The compound was incubated with
mixed gender, pooled liver microsomes from rat and human in the
presence of NADPH for 60 min  at 37 ◦C, at which point microsomal
activity was quenched by the addition of acetonitrile. Control sam-
ples included time zero and 60 min  incubates without NADPH as
well as testosterone incubation samples in order to verify micro-
some functionality. Samples were analyzed by LC/MS along with
multi-wavelength UV detection (214, 240 and 254 nm) in order to
evaluate the metabolism of S9632.
Based on concerted and detailed analysis of the full scan
MS of study samples, S9632 was  not metabolized by the rat or
human microsomes during the 60 min  incubation period. Mass
chromatograms were generated for the common Phase I transfor-
mations of M + 16, M + 32, M − 16, M − 32, M + 18, M − 18, M − 42
and M − 44 (decarboxylation), and M − 141 (O-dealkylation of the
2,2-dimethyl-N-(propan-2-yl)-propanamide moiety). Full scan and
mass chromatograms were examined in detail to support that no
metabolism was  observed above the level of 0.1% of the parent drug.
No Phase I biotransformations of S9632 were observed in either the
rat or human microsomal incubation samples, to the level of 0.1%
of the parent compound; statements of scale (quantitative) assume
that the relative response factor for all metabolites is equivalent for
the mass spectrometry data.
3.2. Pharmacokinetics in Rats
The PK parameters and oral bioavailability of S9632 were eval-
uated after single intravenous administration or up to seven days
of oral administration to Sprague-Dawley rats (CD® [Crl:CD®(SD);
Charles River Laboratories, Hollister, CA]).
For single intravenous administration, male and female
Sprague-Dawley rats (n = 4/sex/group) were given an intravenous(0.2 mL)  were collected from implanted jugular cannulae of each
rat at pre-dose and at approximately 2, 5, 10, 30 min, 1, 2, 4, and
8 h after the intravenous dose. For oral administration, male and
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Fig. 2. Mean plasma concentrations of S9632 on Day 1 after intravenous adminis-
tration to male Sprague-Dawley rats (n = 4).
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po, 100 mg/kgig. 3. Mean plasma concentrations of S9632 on Day 1 after oral administration to
ale Sprague-Dawley rats (n = 3/group).
emale Sprague-Dawley rats (n = 3/sex/dose group) were adminis-
ered daily doses (10, 30, or 100 mg/kg S9632 in 1% methylcelluose,
C)  by oral gavage for seven consecutive days. Blood samples were
ollected from the jugular catheter at pre-dose and approximately
5, 30 min, 1, 2, 4, 8, and 24 h on Days 1 and 7.
S9632 was poorly orally bioavailable (%F = 0.53–1.19%) and
apidly eliminated after either intravenous (t1/2 < 0.27 h) or oral
dministration (t1/2 < 1.39 h). As expected on the basis of its poor
ral bioavailability, systemic exposure to S9632 was relatively low.
or example, at 100 mg/kg/day, the combined mean Cmax on Day 7
as 153.8 ng/mL (0.428 M),  and the combined mean AUC0 − 24 was
32.1 ng·hr/mL. Based on AUClast and Cmax, the exposure to S9632
n plasma was roughly proportional with dose. Exposure (AUClast)
o S9632 was not signiﬁcantly different in either male or female
ats on Day 7 vs Day 1 of dosing. No signiﬁcant accumulation of
9632 was found in plasma after repeated dosing for 7 consecutive
ays. See Table 1 and Figs. 2, 3, and 4.
.3. Relative oral bioavailability of sodium, phosphate, and
emisulfate salts of S9632
The objective of this study was to determine whether the sys-
emic exposure following an oral dose of either the sodium (S3333),
hosphate (S3337), or hemisulfate (S1638) salt forms of S9632 dif-
ers signiﬁcantly from that of the parent compound. Each group
f 4 male Sprague-Dawley rats was treated with a single dose of
0 mg/kg of either S9632, S3333, S3337, or S1638 in 1% MC  by
ral gavage. Blood samples were taken from a jugular catheter at
pproximately 15, 30 min, 1, 2, 4, 8, and 24 h post dose. Plasma
amples were analyzed for S9632 by LC/MS/MS with an internal
tandard (S0176).Fig. 4. Mean plasma concentrations of S9632 on Day 7 after oral administration to
male Sprague-Dawley rats (n = 3/group).
The plasma AUClast and Cmax of sodium salt S3333 relative to that
of the parent compound S9632 was 89.5% and 99.4%, respectively
(after correcting for differences in molecular weight). Similarly, the
plasma AUClast and Cmax of phosphate salt S3337 relative to that of
the parent compound S9632 was  111.9% and 99.9%, respectively.
Finally, the plasma AUClast and Cmax of sulfate salt S1638 relative
to that of the parent compound S9632 was 127.1% and 106.7%,
respectively. Based on AUClast, Cmax and Tmax data, all three salt
forms of S9632 are not signiﬁcantly different and considered to be
bioequivalent to S9632 in terms of systemic exposure. See Table 2.
3.4. Excretion in Rats
Male and female Sprague-Dawley rats (n = 4/sex/group) were
administered 10 mg/kg of S9632 as a suspension in 1% MC
(10 mL/kg) by oral gavage and urine and feces were collected at
four time intervals, 0–8, 8–24, 24–48, and 48–72 h, after dosing.
Fecal homogenate and urine samples were analyzed by LC/MS/MS
with an internal standard (S0176).
An average of 86.2% from male rats and 91.4% from female rats, of
S9632 was  recovered from feces and urine over the combined 72 h
collection period. The vast majority of the compound was excreted
during the 8–24 h time interval, the majority of which was recov-
ered from the feces (an average of 88.4% in feces versus 0.4% in urine,
males and females combined). The trace amounts of S9632 oxida-
tive metabolites (M + 16) were seen in the urine samples but were
not detectable in fecal samples. These results are consistent with
the hypothesis that S9632 is poorly absorbed and mainly excreted
unchanged.
4. Genotoxicity and mutagenicity studies
S9632 was  evaluated for its genotoxic potential through abbre-
viated Ames (2-strains), standard (5-strain) Ames, chromosome
aberration, and micronucleus tests (see Table 3). Due to higher sol-
ubility in DMSO, the sodium salt of S9632 (S3333) was  utilized in
the 5-strain Ames and chromosome aberration assays. The decar-
boxylated impurity, S9379, was  also evaluated in an abbreviated
Ames (2-strains) assay. The data tables for the genotoxicity studies
can be found in the Supplemental material.
4.1. Abbreviated Ames assay
S9632 and impurity S9379 were evaluated for the poten-
tial to induce point mutations or frame shifts in S. typhimurium
strains TA98 and TA100 in a plate incorporation assay in the pres-
ence or absence of metabolic activation (rat liver S9). The assay
was designed to meet the current OECD Guideline for Testing of
1258 A.J. Arthur et al. / Toxicology Reports 2 (2015) 1255–1264
Table 1
Pharmacokinetics of S9632 in Male and Female Sprague-Dawley Rats Following Repeated Administration for 7 Days.
Route Day Dose (mg/kg) Sex Cmax (ng/mL) ± SD Tmax (hr) t1/2 (hr) AUC0-last
(ng·hr/mL) ± SD
AUC0-last/dose
(ng·hr/mL/mg/kg)
%F
iv 1 1.0 M 2036.7 ± 281.9 0.03 0.19 330.6 ± 58 330.6 –
F  2625.8 ± 679.9 0.03 0.27 411.9 ± 116.3 411.9 –
Oral  gavage 1 10 M 12.9 ± 3.2 0.25 1.21 17.9 ± 2.3 1.79 0.54
F  34.0 ± 3.9 0.25 1.17 49.2 ± 7.8 4.92 1.19
30 M  90.0 ± 23.9 0.33 0.88 90.8 ± 11.0 3.03 0.92
F  62.4 ± 25.9 0.42 1.06 95.0 ± 20.4 3.17 0.77
100 M  147.2 ± 86.3 0.33 0.71 176.2 ± 73.8 1.76 0.53
F  268.5 ± 90.7 0.25 0.99 341.1 ± 81.0 3.41 0.83
Oral  gavage 7 10 M 16.2 ± 3.6 0.50 0.84 48.1 ± 33.2 4.81 –
F  32.7 ± 9.7 0.33 1.17 58.9 ± 25.4 5.89 –
30 M  74.5 ± 16.2 0.33 0.94 86.0 ± 8.7 2.87 –
F  77.1 ± 41.7 0.25 1.39 106.8 ± 8.7 3.56 –
100 M  117.9 ± 15.3 0.25 0.72 185.3 ± 15.3 1.85 –
F  189.7 ± 79.5 0.25 0.89 278.9 ± 79.0 2.79 –
Male rat: CL = 51.5 mL/min/kg; Vss = 440.3 mL/kg; Female rat: CL = 42.5 mL/min/kg; Vss = 320.9 mL/kg.
SD  = standard deviation, CL = clearance, Vss = steady-state volume of distribution, %F = bioavailability.
Table 2
Comparison of the Pharmacokinetics of S9632 and its Sodium (S3333), Phosphate (S3337), and Sulfate (S1638) Salts after a Single Oral Administration of 30 mg/kg in Male
Sprague-Dawley Rats.
Compound MW S9632
Equiv. Dose
(mg/kg)
AUClast
(ng·hr/mL)
AUClast/Equiv.
Dose (ng·hr
/mL/mg/kg)
%AUClast
Relative to
S9632
Cmax (ng/mL) Cmax/Equiv.
dose
(ng/mL/mg/kg)
%Cmax
Relative to
S9632
S9632 359.42 30.00 59.57 ± 26.08 1.986 100.0% 38.73 ± 24.50 1.291 100.0%
S3333  381.40 28.27 50.20 ± 6.35 1.776 89.5% 36.28 ± 6.66 1.283 99.4%
S3337  457.41 23.57 52.39 ± 4.85 2.223 111.9% 30.40 ± 3.81 1.290 99.9%
S1638  426.47 25.28 63.83 ± 15.72 2.525 127.1% 34.80 ± 7.55 1.377 106.7%
Table 3
Summary of genotoxicity studies conducted on S9632.
End-Point Test System Concentration/dose Result
Reverse mutation (in vitro) S. typhimurium strains
TA98, TA100, TA1535,
TA1537 and E. coli strain
WP2  uvrA
51–5000 ug/plate, plate
incorporation and
pre-incubation, ±S9a
Negative
Chromosome aberration
(in vitro)
HPBL 125–500 ug/mL, 3 h
exposure ±S9b, 20 h
exposure -S9
Negative
Micronucleus formation
(in vivo)
Male Swiss albino mice
(CD-1)
500–2000 mg/kg bw (oral) Negative
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Ca S9 from rat liver homogenate from male Sprague-Dawley rats treated with Aro
b S9 from rat liver homogenate from male Sprague-Dawley rats treated with phe
hemicals—471, Bacterial Reverse Mutation Test [14]. Both com-
ounds were tested over a range of concentrations up to and
ncluding 5000 g/plate. For S9632, neither bacterial toxicity nor
n increase in the number of revertant colonies with or with-
ut metabolic activation was observed. For S9379, cytotoxicity
reduction in the background lawn) was observed at 5000 g/plate
n TA98 and TA100 without metabolic activation. With S9379,
here was no increase in the number of revertant colonies as
ompared with the vehicle control in either strain with or with-
ut metabolic activation. Positive and vehicle controls yielded the
xpected results. It was concluded that S9632 and S9379 were not
utagenic to S. typhimurium strains TA98 and TA100 under the test
onditions.
.2. Bacterial reverse mutation test (5-strain Ames)
The sodium salt of S9632 (S3333) was evaluated for the poten-
ial to induce point mutations in S. typhimurium strains, TA98,
A100, TA1535, TA1537 and Escherichia coli strain WP2  uvrA in the
resence and absence of metabolic activation (rat S9). The assay
as designed to meet the current OECD Guideline for Testing of
hemicals—471, Bacterial Reverse Mutation Test [14]. The bacte-254.
bital/5,6-benzoﬂavone.
ria were treated with each test article at doses ranging from 0 to
5000 g/plate, in the presence and absence of metabolic activation.
No visible precipitate was  formed and there were no obvious
toxicity observed at any concentration. For the plate incorporation
test, with or without metabolic activation, S3333 did not produce
any increases in revertants over the concurrent negative controls.
The preincubation test conﬁrmed the negative results. The negative
controls for each tester strain were within the historical nega-
tive control data. All concurrent positive controls induced at least
3.1-fold increase in colony counts per plate when compared to
the corresponding negative controls and were at levels similar to
the historical positive control data. Thus, it was concluded that
S3333 was not mutagenic to S. typhimurium strains TA98, TA100,
TA1535, TA1537 and E. coli strain, WP2  uvrA at concentrations up
to 5000 g/plate, both in the presence and absence of metabolic
activation with rat liver S9.
4.3. Chromosome aberration testS3333 was  investigated for the potential to induce struc-
tural and numerical chromosome aberrations in human peripheral
blood lymphocytes (HPBL) in both the presence and absence of a
metabolic activation (rat S9). The experimental design followed the
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ECD Guideline for the Testing of Chemicals—473, In Vitro Mam-
alian Chromosome Aberration Test [15].
HPBL were treated with S3333 at concentrations ranging from
 to 500 g/mL for 3 and 20 h in the non-activated test system,
nd for 3 h in the presence of S9-activated test system. Solvent
nd positive control (mitomycin C, -S9; cyclophosphamide, +S9)
ultures were also included. Only the highest exposure concentra-
ion of 500 g/mL produced precipitates in the treatment medium
t the beginning of the treatment period. With all three test con-
itions, Relative Cell Growth (RCG) of ≥72% and Relative Mitotic
ndex of ≥75% were seen at the highest concentration of S3333.
ased on these ﬁndings, the three highest concentrations (125, 250
nd 500 g/mL) of S3333 were chosen for chromosomal aberration
nalysis for each condition. Therefore, the test article was tested at
he limit of solubility.
The percentage of cells with structural or numerical aberrations
n the test article-treated groups was not signiﬁcantly increased
elative to solvent control at any dose level. The positive and solvent
ontrols fulﬁlled the requirements for a valid test. Based on the
ndings of this study, S3333 was concluded to be negative for the
nduction of structural and numerical chromosome aberrations in
oth non-activated and S9-activated test systems in the in vitro
ammalian chromosome aberration test using human peripheral
lood lymphocytes.
.4. Micronucleus assay
S9632 was  evaluated for potential clastogenic activity and/or
nterference with the spindle apparatus as measured by its ability
o increase the incidence of micronucleated polychromatic erythro-
ytes (mnPCEs) in the bone marrow of male and female mice. The
tudy was designed to meet the current OECD Guideline for the
esting of Chemicals—474, Mammalian Erythrocyte Micronucleus
est [16]. Male and female Swiss albino (CD-1) mice (Charles River,
anada) were treated with S9632 as suspension in 1% MC/puriﬁed
ater (20 mL/kg body weight dose volume) by oral gavage for both
he dose range ﬁnding and deﬁnitive phases of the study. In the
eﬁnitive phase of the study, 1% MC  was used as the vehicle (neg-
tive) control and cyclophosphamide, at a dose of 70 mg/kg, was
sed as the positive control article. Animals were observed for signs
f toxicity during the course of the study.
In a preliminary dose range ﬁnding study, mice (2 ani-
als/sex/group) were dosed at 500, 1000 and 2000 mg/kg. There
as no toxicity noted up to 2000 mg/kg, and no difference in
oxicity between genders. In the deﬁnitive phase, male mice (21
nimals/group) were treated at 500, 1000 or 2000 mg/kg, and
nimals from each group were sacriﬁced at 24, 36 or 48 h after
osing (7 animals per time point). For each sacriﬁced animal,
one marrow was recovered and pooled from both femora. Bone
arrow smears were prepared, ﬁxed and stained for evaluation.
wo thousand polychromatic erythrocytes (PCEs) per animal were
cored for the presence of micronuclei. In addition, the number
f normochromatic erythrocytes with micronuclei were scored.
he polychromatic/normochromatic ratio was established (per 200
ells). The presence/absence of micronuclei was also conﬁrmed by
pplying a DNA-speciﬁc stain to slides from the positive control
roup, and the test high dose group, for the samples collected at
4 h.
There was no S9632 dose-related increase in micronucleated
CEs. There were no statistically signiﬁcant differences in the num-
er of PCEs with micronuclei between the test article (all three dose
evels) and the negative control group. There was  no statistically
igniﬁcant change in the ratio of PCEs to normochromatic erythro-
ytes in the test article-treated groups compared to the negative
ontrol group, suggesting that the test article did not inhibit ery-
hropoiesis. In the positive control group, this ratio was decreasedorts 2 (2015) 1255–1264 1259
at the 48-h time point, indicating bone marrow suppression. There
were statistically signiﬁcant differences (p ≤ 0.05) at 24, 36 and
48 h in the number of PCEs with micronuclei in the positive con-
trol group when compared to both the negative control group and
the test article at all three dose levels. Based on these results, the
test article, S9632, did not induce micronuclei at dose levels up
to 2000 mg/kg, administered by as a single dose by oral gavage to
mice. The test article was  not clastogenic and did not interact with
the mitotic spindle.
5. In Vivo toxicological studies
S9632 was  evaluated in 28-day dose-range ﬁnding and 90-day
toxicology studies in rats in compliance with the United States Food
and Drug Administration (FDA) Guidelines [6] Toxicological Princi-
ples for the Safety of Food Ingredients. S9632 was  also evaluated for
potential embryo/fetal toxicity in a gestational developmental toxi-
city study in rats. The developmental toxicity study consisted of two
phases, a range-ﬁnding study and a deﬁnitive study in which the
test animals were evaluated for both maternal toxicity and effects
on embryo/fetal development (see Table 4). Summary data tables
for 90-day toxicology and deﬁnitive developmental toxicity studies
for S9632 can be found in the Supplemental material.
5.1. Subchronic toxicology studies
5.1.1. 28-Day dose-range ﬁnding toxicity study
The purpose of this study was  to evaluate the potential systemic
toxicity of S9632 in rats after dietary administration for 28 days in
order to select doses for 90-day subchronic toxicity studies in rats.
Three treatment groups of male and female CD® [Crl:CD®(SD)] rats
(n = 5/sex/group; Charles River, Portage, Michigan) were adminis-
tered S9632 in the diet at dose levels of 10, 30, or 100 mg/kg/day.
One additional group of ﬁve animals/sex served as the control and
received the vehicle diet. The vehicle or test article diet was avail-
able ad libitum for 28 consecutive days.
Survival, clinical observations, body weight, food consumption,
clinical chemistry, ophthalmic examination, organ weights, and
macroscopic evaluations of all animals were used to assess poten-
tial toxicity. The livers (0 and 100 mg/kg/day dose groups only) and
any gross lesions of all animals were subjected to histopathological
examination.
No test article-related effects were noted for any parame-
ter examined. One female at 100 mg/kg/day exhibited mildly
increased lymphocytes but being an isolated incidence this was
not considered related to test article administration. One male at
100 mg/kg/day exhibited markedly increased bile acids and mild to
moderate increases of aspartate aminotransferase, alanine amino-
transferase, -glutamyltransferase, and sorbitol dehydrogenase.
These are all related to liver function and injury, but because this
was an isolated occurrence they were believed to be incidental in
this animal and not test article related. Group mean spleen weights
were increased in males of the 100 mg/kg/day group which was  the
result of one animal having a spleen weight approximately twice
that of the other animals of the group. This is the same animal noted
above with elevated bile acid and liver enzyme levels; the increased
spleen weight in this animal was  not considered to be test article
related. As a result, the no-observed-effect-level (NOEL) following
28 days of dietary administration was 100 mg/kg/day, the highest
dose level tested, in male and female rats.
5.1.2. 90-Day subchronic toxicity study
The purpose of this study was to evaluate the potential sub-
chronic toxicity and toxicokinetic proﬁle of S9632, in rats after
dietary administration for 90 consecutive days. Test article was
administered in the diet to four groups of twenty male and twenty
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Table 4
Summary of subchronic and developmental toxicity studies conducted on S9632.
Study Species/Gender (N value) Dose Findings
28-Day dose
range-ﬁnding
toxicity study
Male & Female
Sprague-Dawley Rats
−5  animals/sex/group
10, 30, 100 mg/kg/day
(food ad-mix)
No test-article related
ﬁndings; NOEL = 100
mg/kg/day
90-Day
sub-chronic
toxicity study
Male & Female
Sprague-Dawley Rats
Main study:
−20 animals/sex/group
TK satellite group:
−6 animals/sex/group
30, 60, 100 mg/kg/day
(food ad-mix)
No test-article related
ﬁndings; NOEL = 100
mg/kg/day
Dose  range-ﬁnding
developmental
toxicity study
Bred Female
Sprague-Dawley Rats
−8  animals/group
125, 250, 500, 1000
mg/kg/day
(oral gavage)
No maternal toxicity or
effects on intrauterine
growth and survival up to
1000 mg/kg/day
Deﬁnitive Bred Female 250, 500, 1000 mg/kg/day
(oral gavage)
NOEL for both maternal
toxicity and embryo/fetal
develop-
ment = 1000 mg/kg/day
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Fig. 5. Mean body weights of male Sprague-Dawley rats receiving S9632 in diet for
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toxicity  study
Sprague-Dawley Rats −25
animals/group
emale Sprague-Dawley [Crl:CD®(SD)] rats at dose levels of 0 (basal
iet), 30, 60, or 100 mg/kg/day for a 90-day period. Additionally,
ne control group of three animals/sex and three treated groups
f six animals/sex/group served as toxicokinetic (TK) animals and
eceived the vehicle or test article diet in the same manner as the
ain study groups at respective dose levels of 0 (control), 30, 60,
r 100 mg/kg/day.
Survival, clinical observations, a functional observational bat-
ery (including, but not limited to, evaluation of activity, arousal,
utonomic and physical function, neuromuscular function, sal-
ation, and respiration), ophthalmic examination, body weight
ain, food consumption, hematology, clinical chemistry, urinaly-
is, organ weights, macroscopic examination, and histopathologic
valuation were performed to assess potential toxicity.
In the TK study, there were no consistent gender differences in
he TK parameters calculated for male and female rats on Day 7 or
n Day 90 (Table 5). On Day 90, systemic exposure, as estimated
y AUC0–24 and Cmax, increased in approximate proportion to the
ncrease in dose between 30 and 100 mg/kg/day, but tended to be
reater than dose proportional at the 100 mg/kg/day dose on Day
. Combined mean Tmax ranged from 1.50 to 3.00 h on Day 7 and
rom 1.50 to 7.50 h on Day 90. Combined mean Tmax was generally
onger at 60 and 100 mg/kg/day than at 30 mg/kg/day on Day 90.
onsistent with results from PK studies in rats, systemic exposure
o S9632 was relatively low. For example, at 100 mg/kg/day, the
ombined mean Cmax on Day 7 was 114 ng/mL (0.317 M),  and the
ombined mean AUC0–24 was 1040 ng·hr/mL. Systemic exposure to
9632 was higher on Day 90 than on Day 7. Combined mean accu-
ulation ratios ranged from 1.15 to 2.79 for AUC0–24, and ranged
rom 1.77 to 5.21 for Cmax.
There were no test article-related effects for any parameter
xamined, including clinical signs, body weights (see Figs. 5 and 6),
phthalmic examinations, hematology parameters, coagulation
imes, clinical chemistry parameters, urinalysis parameters, organ
eight, macroscopic or microscopic changes, or in the func-
ional observation battery in either sex at any dose level. As a
esult, the NOEL following 13-weeks of dietary administration was
00 mg/kg/day, the highest dose level tested, in male and female
ats.
.2. Developmental toxicity studies.2.1. Dose range-ﬁnding developmental toxicity study
The objective of the study was to determine dosage levels of
9632 to be evaluated in a deﬁnitive developmental toxicity studyFig. 6. Mean body weights of female Sprague-Dawley rats receiving S9632 in diet
for  13 weeks (n = 20/group).
conducted in rats. The test article, S9632, in the vehicle (1% MC)
was administered orally by gavage to 4 groups of 8 bred female
Crl:CD(SD) rats once daily from gestation Days 6 through 20,
with dosage levels of 125, 250, 500, or 1000 mg/kg/day. A con-
current control group composed of 8 bred females received the
vehicle on a comparable regimen. The females were approximately
13 weeks of age when paired for breeding. Positive evidence of
mating was  conﬁrmed by the presence of a vaginal copulatory
plug or the presence of sperm in a vaginal lavage. The day on
which evidence of mating was identiﬁed was termed gestation Day
0. All animals were observed for mortality, moribundity, clinical
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Table  5
Toxicokinetics of S9632 in male and female Sprague-Dawley rats (food ad-mix).
Day Dose Level (mg/kg/day) Sex Cmax (ng/mL) Tmax (hr) AUC(0–24) (ng·hr/mL) AUC0-24/dose (ng·hr/mL/mg/kg)
7 30 Male 18.4 3.00 250 8.34
Female 7.47 0 105 3.5
Combined 12.9 1.5 178 5.92
60 Male 15.9 0 228 3.79
Female 38.5 6.00 566 9.43
Combined 27.2 3.00 397 6.61
100 Male 79.2 3.00 915 9.15
Female 149 0 1170 11.7
Combined 114 1.50 1040 10.4
90  30 Male 46.8 0 293 9.75
Female 31.2 3.00 389 13.0
Combined 39.0 1.50 341 11.4
60 Male 146 6.00 1050 17.5
Female 47.5 3.00 549 9.14
Combined 97.0 4.50 798 13.3
3.00 1000 10.0
12.0 1400 14.0
7.50 1200 12.0
o
D
u
f
p
a
l
m
2
w
g
2
c
s
s
l
n
ﬂ
m
s
ﬁ
f
a
a
c
o
s
a
5
o
s
t
a
m
g
b
P
3
m
2
c
225
275
325
375
425
-1 2 5 8 11 14 17 20 23
M
at
er
na
l B
od
y 
W
ei
gh
t (
g)
Gestational Day
0 mg/kg/ day
250 mg/kg/ day
500 mg/kg/ day
1000 mg/k g/day
Fig. 7. Oral (Gavage) Developmental Toxicity Study of S9632 in Rats: Mean maternal100 Male 231 
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Combined 162 
bservations, body weights, and food consumption. On gestation
ay 21, a laparohysterectomy was performed on each female. The
teri, placentae, and ovaries were examined, and the numbers of
etuses, early and late resorptions, total implantations, and cor-
ora lutea were recorded. Gravid uterine weights were recorded,
nd net body weights and net body weight changes were calcu-
ated. The fetuses were weighed, sexed, and examined for external
alformations and developmental variations.
All females survived to the scheduled necropsy on gestation Day
1. No remarkable clinical ﬁndings were observed, and mean body
eights, body weight gains, net body weights, net body weight
ains, gravid uterine weights, and food consumption in the 125,
50, 500 and 1000 mg/kg/day groups were unaffected by test arti-
le administration. No macroscopic ﬁndings were noted at the
cheduled necropsy on gestation Day 21. Intrauterine growth and
urvival were unaffected by test article administration at all dosage
evels. A single low-weight fetus in the 1000 mg/kg/day group was
oted with craniorachischisis, microphthalmia, gastroschisis, tarsal
exure, bent tail, and anal atresia. There were no other external
alformations or external developmental variations noted in this
tudy.
There were no remarkable maternal clinical or macroscopic
ndings and mean maternal body weight, body weight gain, and
ood consumption were unaffected by test article administration
t all dosage levels evaluated. Additionally, intrauterine growth
nd survival, and fetal morphology were unaffected by test arti-
le administration at all dosage levels tested. Based on the results
f this study, dosage levels of 250, 500 and 1000 mg/kg/day were
elected for a deﬁnitive embryo/fetal development study of S9632
dministered orally by gavage to bred Crl:CD(SD) rats.
.2.2. Deﬁnitive developmental toxicity study
The objective of the study was to determine the potential
f S9632 to induce developmental toxicity after maternal expo-
ure from implantation to one day prior to expected parturition,
o characterize maternal toxicity at the exposure levels tested,
nd to determine a no-observed-adverse-effect-level (NOAEL) for
aternal and developmental toxicity. This study was  conducted in
eneral accordance with the OECD guidelines [18] and the FDA Red-
ook [4], and in compliance with the FDA GLP regulations 21CFR
art 58 and OECD guidelines [17].
S9632, was administered orally by gavage (in vehicle 1% MC)  to groups of 25 bred female Crl:CD(SD) rats twice daily (approxi-
ately 4 h apart at 10 mL/kg/dose) from gestation days 6 through
0, at dosage levels 250, 500, or 1000 mg/kg/day. A concurrent
ontrol group composed of 25 bred females received the vehi-body weights during gestation (n = 25/group).
cle on a comparable regimen. The females were approximately 13
weeks of age when paired for breeding. Positive evidence of mat-
ing was conﬁrmed by the presence of a vaginal copulatory plug
or the presence of sperm in a vaginal lavage. The day on which
evidence of mating was  identiﬁed was termed gestation Day 0. All
animals were observed for mortality, moribundity, clinical observa-
tions, body weights, and food consumption. On gestation Day 21, a
laparohysterectomy was performed on each female. The uteri, pla-
centae, and ovaries were examined, and the numbers of fetuses,
early and late resorptions, total implantations, and corpora lutea
were recorded. Gravid uterine weights were recorded, and net
body weights and net body weight changes were calculated. The
fetuses were weighed, sexed, and examined for external, visceral,
and skeletal malformations and developmental variations.
All females survived to the scheduled necropsy on gestation Day
21. No test article-related clinical or macroscopic ﬁndings were
noted at any dosage level. Mean maternal body weights (Fig. 7),
body weight gains, gravid uterine weights, and food consumption
were unaffected by test article administration at all dosage levels.
No test article-related ﬁndings were noted on intrauterine growth
and survival and fetal morphology at any dosage level. Parame-
ters evaluated included post-implantation loss, live litter size, mean
fetal body weights, and fetal sex ratios (Table 6 and Fig. 7).
The mean litter proportion of late resorptions in the
500 mg/kg/day group (2.8% per litter) was above the maximum
mean value in the laboratories historical control data (0.5% per lit-
ter); however, this did not occur in a dose-related manner, the value
was primarily due to 1 litter with 64.3% late resorptions, and the
1262 A.J. Arthur et al. / Toxicology Reports 2 (2015) 1255–1264
Table 6
Developmental Toxicity Study of S9632 in Rats: summary of fetal data.
Dose group
(mg/kg/d)
Fetuses Sex Viable
fetuses
Dead
fetuses
Resorptions Post-
implant.
loss
Implant.
sites
Corpora
Lutea
Pre-
implant.
loss
Fetal
Wt.  (g)
No. of
gravid
females
M F Early Late
0 Total 192 182 374 0 9 2 11 385 418 33 NA 25
Mean  7.7 7.3 15.0 0 0.4 0.1 0.4 15.4 16.7 1.3 5.6
S.D.  2.10 2.49 2.39 0 0.49 0.40 0.71 2.22 2.70 1.77 0.30
S.E.  0.42 0.50 0.48 0 0.10 0.08 0.14 0.44 0.54 0.35 0.06
250 Total  189 169 358 0 24 0 24 382 407 25 NA 25
Mean  7.6 6.8 14.3 0 1.0 0 1.0 15.3 16.3 1.0 5.5
S.D.  2.10 2.11 2.21 0 0.98 0 0.98 2.13 2.26 1.35 0.32
S.E.  0.42 0.42 0.44 0 0.20 0 0.20 0.43 0.45 0.27 0.06
500 Total  177 184 361 0 12 10 22 383 421 38 NA 25
Mean  7.1 7.4 14.4 0 0.5 0.4 0.9 15.3 16.8 1.5 5.4
S.D.  2.25 2.20 2.48 0 0.71 1.80 1.83 1.44 2.79 2.14 0.50
S.E.  0.45 0.44 0.50 0 0.14 0.36 0.37 0.29 0.56 0.43 0.10
1000 Total  181 194 375 0 18 0 18 393 413 20 NA 25
Mean  7.2 7.8 15.0 0 0.7 0 0.7 15.7 16.5 0.80 5.6
S.D.  1.85 2.77 1.83 0 0.98 0 0.98 1.77 1.81 1.08 0.33
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an average of 88.4% of the dose was recovered in feces, and 0.4%S.E.  0.37 0.55 0.37 0 0.20
A = not applicable.
ifference from the concurrent control group was not statistically
igniﬁcant.
The numbers of fetuses (litters) available for morphological
valuation were 374(25), 358(25), 361(25) and 375(25) in the
ontrol, 250, 500 and 1000 mg/kg/day groups, respectively. Malfor-
ations were observed in 0(0), 1(1), 1(1), and 3(3) fetuses (litters)
n these same respective dose groups and were considered spon-
aneous in origin. In the 250 mg/kg/day group, malformation of
nophthalmia (right) was observed in one fetus. However, this ﬁnd-
ng was not considered to be test-article related because it occurred
n single fetus in a manner that was not dose-related, and mean
itter proportions were within the laboratories historical control
ata ranges. No other external malformations were observed at any
osage level. No external developmental variations were noted in
his study.
There were no test article-related soft tissue malformations or
ariations noted for fetuses at any dosage level. One fetus in the
000 mg/kg/day group had an interrupted aortic arch in which
he brachiocephalic trunk and left carotid arteries arose from the
scending aorta, the left subclavian arose from the descending
orta, and the ductus arteriosus communicated with the descend-
ng aorta. In addition, one fetus in the 500 mg/kg/day group had a
tenotic pulmonary trunk. These ﬁndings occurred in single fetuses
nd the mean litter proportions of these ﬁndings were not statis-
ically signiﬁcantly different from the concurrent control group.
herefore, these ﬁndings were not attributed to test article admin-
stration. No other visceral malformations were noted at any dosage
evel. Visceral developmental variations noted in the test article-
reated groups, including renal papilla(e) not developed and/or
istended ureter(s), accessory lobule(s) of the liver, and major
lood vessel variation, were noted infrequently, in similar frequen-
ies in the concurrent control group, and/or in a manner that was
ot dose-related. The mean litter proportion of renal papilla(e)
ot developed and/or distended ureter(s) in the 250 mg/kg/day
roup (4.3% per litter) was above the maximum mean value in
he laboratory’s historical control data (3.5% per litter). However,
his result did not occur in a dose-related manner and the mean
itter proportion was not statistically signiﬁcantly different from
he concurrent control group. Therefore, no visceral developmental
ariations were attributed to test article administration.
There were no test article-related skeletal malformations or
ariations noted for fetuses at any dosage level. One fetus in
he 1000 mg/kg/day group had sternoschisis (sternal band nos. 1 0.20 0.35 0.36 0.22 0.07
through 6 not joined) and another fetus in the same dose group
had a bent scapula (bilateral) and bent limb bones (left femur and
left and right radius, ulna, and humerus). Skeletal variations were
observed with similar frequency in all groups, including the control
group, and consisted mainly 14th rudimentary rib(s), 7th cervical
rib(s), and sternebra(e) malaligned (slight or moderate). The afore-
mentioned visceral and skeletal malformations and variations were
not considered test article-related because they were noted in sin-
gle fetuses, not in a dose-related manner, and/or the mean litter
proportions were within the laboratory’s historical control data
ranges. A detailed summary of all of the external, visceral, and skele-
tal malformations and variations seen in this study can be found in
the Supplemental Data section.
Based on the lack of test article-related effects at any dosage
level, a dosage level of 1000 mg/kg/day, the highest dosage level
evaluated, was  considered to be the NOEL for maternal toxicity and
embryo/fetal development when S9632 was administered orally by
gavage to bred Crl:CD(SD) rats.
6. Discussion
Based on in vitro studies with rat and human liver micro-
somes, S9632 is a poor substrate for cytochrome P450 oxidative
enzymes with no metabolism observed above the level of 0.1% after
a 60 min  incubation period. After intravenous administration to
male and female rats, the mean plasma clearance of S9632 is 93.6%
(males) and 77.3% (females) of hepatic blood ﬂow [2] resulting in an
apparent plasma half-life (t1/2) of only 0.19–0.27 h. The volume of
distribution at steady state (Vss) was 440.3 mL/kg in male rats and
320.9 mL/kg in female rats, 0.48–0.66 times total body water [2].
After oral administration to the rat, the plasma elimination half-
life (t1/2) for S9632 ranged from 0.71–1.39 h and the AUC0-last and
Cmax increased roughly in proportion to dose after oral administra-
tion in the rat. Bioavailability (%F) remained relatively ﬁxed with
increasing oral dose, ranging from 0.53% to 1.19%.
In order to exclude the possibility that S9632 is undergoing pre-
systemic metabolism by the gut microﬂora, the amount of S9632
recovered in the feces and urine following a single oral dose was
investigated in male and female rats. At an oral dose of 10 mg/kg,recovered in urine in the ﬁrst 24 h. The trace amounts of S9632
oxidative metabolites (M + 16) were seen in the urine samples but
were not detectable in fecal samples. These results suggest that
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development in rats. The results of the 90-day subchronic toxic-A.J. Arthur et al. / Toxicolo
9632 does not undergo signiﬁcant metabolism in the gut and is
argely excreted unchanged. Taken together with the compound’s
ather low systemic bioavailability after oral administration, it is
ikely that S9632 is poorly absorbed in the intestinal tract.
S9632 was evaluated for its genotoxic potential through a stan-
ard battery of in vitro and in vivo genotoxicity assays which
ncluded an abbreviated Ames (S. typhimurium strains TA98 and
A100), a bacterial reverse mutation assay (S. typhimurium strains,
A98, TA100, TA1535, TA1537 and E. coli strain WP2  uvrA), a chro-
osome aberration test in HPBL, and an in vivo micronucleus test
n mice. S9632 did not exhibit any genotoxic concerns, i.e.  the com-
ound was not found to be mutagenic or clastogenic in vitro, and
id not induce micronuclei or interact with the mitotic spindle in
one marrow erythrocytes after oral administration of S9632 at a
ose of 2000 mg/kg to male CD-1 mice.
The doses of S9632 selected for the 28- and 90-day toxicology
tudies were designed to provide a high margin of safety rather
han deﬁne a maximum tolerated dose (MTD) in rats. Applying
 1000-fold margin of exposure in extrapolating animal data to
umans to account for species differences in susceptibility, numer-
cal differences in population ranges between the test animals and
he human population, the greater variety of complicating disease
rocesses in the human population, and the possibility of syner-
istic action among food additives, is believed to be an adequate
argin of safety for most substances proposed for use in food
12,3].
The Joint FAO/WHO Expert Committee on Food Additives
JECFA) employs both the maximized survey-derived intake (MSDI)
ethod and single portion exposure technique (SPET) as measures
f dietary exposure to ﬂavouring agents for use in their safety
valuation of these compounds [10]. The MSDI is based on the
eported amount of a ﬂavouring agent introduced into the food
upply per year in speciﬁc regions of the world and provides a per
apita estimate of the exposure to the ﬂavouring agent, assuming
hat 10% of the relevant population would consume foods con-
aining the ﬂavouring agent. However, in many cases the MSDI is
elieved to underestimate the dietary exposure to some ﬂavouring
gents. The SPET was developed to account for speciﬁc consumer
atterns of behaviour with respect to food consumption and pos-
ible uneven distribution of dietary exposure for consumers of
oods containing ﬂavouring agents [10]. The SPET provides an esti-
ate of the dietary exposure for an individual who consumes a
peciﬁc food product containing the ﬂavouring agent every day
nd combines an average added use level with the standard por-
ion size for a particular food category. The dietary exposure from
he single food category leading to the highest dietary exposure
rom one portion is taken as the SPET estimate. Based on the SPET
alue obtained from non-alcoholic beverages, JECFA estimated the
ietary exposure of S9632 (JECFA No. 2204) as 2400 g/day [11].
herefore, based on this calculation, a NOAEL of 100 mg/kg bw/day
n a 90 day sub-chronic toxicology study would be 2500 times the
stimated dietary exposure to S9632 when used as a ﬂavouring
gent.
In the 28-day range-ﬁnding toxicity study of S9632 in male and
emale Sprague-Dawley rats, the test article was administered as a
ood ad-mix at dose levels of 10, 30 and 100 mg/kg/day. There were
o treatment-related changes in mortality, clinical observations,
ody weights, body weight gains, food consumption, urinalysis
arameters, hematology parameters, or clinical chemistry param-
ters in the 28-day dose-range ﬁnding study. There were also no
est article-related organ weight or macroscopic changes noted at
ny dose level, and no abnormalities observed after gross necropsy
nd the histopathological examination of the liver of all animals
as unremarkable. The NOEL for S9632 in the 28-day range-ﬁnding
tudy was 100 mg/kg/day.orts 2 (2015) 1255–1264 1263
Guided by the ﬁndings of the 28-day range-ﬁnding toxicity
study, S9632 was  evaluated in a 90-day subchronic toxicology
study in both male and female Sprague-Dawley rats (20 ani-
mals/sex/group) at 30, 60, and 100 mg/kg/day, administered as a
food ad-mix. The study included a functional observation battery
and motor activity assessments, in addition to the evaluation of
body weight gain, food consumption, hematology, clinical chem-
istry, urinalysis, organ weights, macroscopic and histopathological
examination of at least 53 tissues (control and high dose ani-
mals only; see Supplementary Data for list of tissues examined
histopathologically). The study also included a TK assessment of
compound exposure on a group of satellite animals on Days 7 and
90.
On Day 7, the systemic exposure (AUC) to S9632 observed in
the TK study conducted as part of the 90-day subchronic toxicol-
ogy study where the compound was  administered as a food ad-mix
was signiﬁcantly higher (2.9–5.3 fold) than in the repeat dose PK
study performed by oral gavage, suggesting that the absorption of
S9632 may  be increased by the presence of food. Alternatively, the
higher exposure in the dietary study may  be due to the slow absorp-
tion over a longer period when being consumed throughout the
day rather than received as a bolus dose. There were no consistent
gender differences seen in either the repeat PK or TK studies. In
both studies, systemic exposure to S9632 (estimated by AUC0–24 or
AUClast and Cmax) was  relatively low.
In the 90-day study, there were no test article-related effects
among clinical signs, body weights, ophthalmic examinations,
hematology parameters, coagulation times, clinical chemistry
parameters, or urinalysis parameters, or in the functional obser-
vation battery in either sex at any dose level. There were no test
article-related organ weight, macroscopic or microscopic changes
in the tissues examined noted at any dose level. Therefore, the
results of the 90-day subchronic toxicity study established a NOEL
for S9632 of 100 mg/kg/day (the highest dose evaluated), for both
male and female Sprague-Dawley rats.
S9632 was  also evaluated for its potential to induce devel-
opmental toxicity when administered orally to bred female rats
from gestation Days 6 through 20, at dosage levels 250, 500, or
1000 mg/kg/day. No test article-related clinical or macroscopic
ﬁndings were noted at any dosage level. Mean maternal body
weights, body weight gains, gravid uterine weights, and food
consumption were unaffected by test article administration at
all dosage levels. No test article-related ﬁndings were noted on
intrauterine growth and survival and fetal morphology at any
dosage level. There were no test article-related external malfor-
mations, soft tissue, or skeletal malformations noted for fetuses at
any dosage level. Based on the lack of adverse maternal toxicity
or effects on intrauterine growth and survival and fetal mor-
phology at any dosage level, a dosage level of 1000 mg/kg/day
(the highest dosage level evaluated) was  considered to be the
NOEL for S9632 for both maternal toxicity and embryo/fetal
development.
7. Conclusions
S9632 demonstrated a lack of genotoxicity with or without
metabolic activation in vitro at concentrations that greatly exceed
those observed in rat plasma following oral administration of S9632
at doses up to 100 mg/kg. In addition, S9632 demonstrated a lack of
genotoxicity in mice at an oral dose of 2000 mg/kg, and had a NOEL
of 1000 mg/kg/day for both maternal toxicity and embryo/fetality study established a NOEL of 100 mg/kg/day (the highest dose
evaluated), for male and female rats. Assuming that the sys-
temic exposure to S9632 after oral administration to humans is
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